Clinical Trial

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

Withdrawn Phase 3
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision
Summary
This is an open-label, randomized, phase 3 study of intravesical BCG plus ANKTIVA (experimental arm) versus BCG alone (control arm) in participants who have histologically confirmed, BCG-naïve/BCG-exposed high-grade Ta/T1 papillary disease. The purpose of this study is to evaluate the contribution of effect of neoadjuvant ANKTIVA plus BCG experimental therapy in papillary NMIBC.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-05-20
notable Enrollment reduced: 688 -> 0 participants 2026-05-20
Trial Details
NCT Number NCT07551544
Lead Sponsor ImmunityBio, Inc.
Conditions NMIBC
Start Date 2026-05-15
Primary Completion 2032-05 (estimated)
Study Completion 2032-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-19